STOCK TITAN
The best stock market news and trading tools all in one place—your must-have platform for investing success.
A must-have platform for stock market information, offering the best tools and updates to supercharge your trading.
Your trusted source for the best stock market news, trading tools, and expert advice. Everything traders need, in one place.
  1. Home
  2. News
  3. OFIX

Orthofix Medical Inc. - OFIX STOCK NEWS

Welcome to our dedicated page for Orthofix Medical news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Medical stock.

Orthofix Medical Inc. (NASDAQ: OFIX) is a leading medical device company providing orthopedic and spine solutions to healthcare providers worldwide. Founded in 1980 by orthopedic researcher Giovanni De Bastiani in Verona, Italy, the company has expanded to over 900 employees and operates in the U.S., Italy, Germany, France, the UK, Brazil, Australia, and Puerto Rico. Orthofix's products serve patients in more than 70 countries, focusing on enhancing patient quality of life through innovative medical solutions.

The company is structured into four strategic business units:

  • BioStim: Offering bone growth stimulators using pulsed electromagnetic field technology.
  • Biologics: Providing regenerative tissue products and biological solutions for bone and soft tissue repair.
  • Extremity Fixation: Specializing in devices for fracture repair, deformity correction, and bone reconstruction.
  • Spine Fixation: Delivering comprehensive solutions for spinal implants and bone healing therapies.

Orthofix is committed to clinical research and innovation, continuously introducing new products to meet the evolving needs of the medical community. The company maintains strong partnerships with esteemed institutions like the Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation, reflecting its dedication to advancing orthopedic and spine care.

The majority of Orthofix's sales come from its global spine segment, primarily in the United States. The company's products are distributed through sales representatives, distributors, and subsidiaries across North America, Europe, and other international markets. Orthofix's solutions cater to hospitals, physicians, healthcare providers, and patients, aiming to improve treatment outcomes and patient well-being.

Latest News: Stay updated with the latest developments, product launches, and financial reports from Orthofix Medical Inc. to keep track of the company's performance and strategic initiatives.

News

Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company

Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ: OFIX) announced the appointment of three new independent directors to the Company’s Board. The new directors bring substantial finance, strategic development, healthcare and medical technology experience to further advance Orthofix’s position as a leading global spine and orthopedics company. The appointments follow constructive engagement and entry into a cooperation agreement with Engine Capital Management, LP, one of the Company’s largest shareholders. The three new independent directors joining the Orthofix Board are: Alan Bazaar, Chief Executive Officer of wealth management firm Hollow Brook Wealth Management LLC; Michael Finegan, Chief Executive Officer of Acera Surgical and former Chief Strategy Officer of Orthofix; and Charles Kummeth, President and Chief Executive Officer of Bio-Techne Corporation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

Orthofix Announces Publication in The Spine Journal of Five-Year Data for the M6-C Artificial Cervical Disc

Rhea-AI Summary
Orthofix Medical Inc. (OFIX) announces the publication of the five-year results from the U.S. clinical study comparing the M6-C artificial cervical disc with anterior cervical discectomy and fusion (ACDF). The study demonstrates superior clinical success of the M6-C disc at 60 months compared to ACDF patients, with significant improvements in neck and arm pain, function, and quality of life scores. The M6-C artificial disc has received U.S. FDA approval and has had over 100,000 implantations worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
News

Orthofix Names Massimo Calafiore as President and Chief Executive Officer

Rhea-AI Summary
Orthofix Medical Inc. (OFIX) has announced the appointment of Massimo Calafiore as the incoming President and CEO. Mr. Calafiore, currently the CEO of LimaCorporate S.p.A., will take over in early 2024, following LimaCorporate's acquisition by Enovis Corporation. The board unanimously chose Mr. Calafiore for his proven track record in delivering value creation and extensive knowledge of the orthopedics and spine industry. His appointment is expected to drive significant profitable growth and enhance shareholder value for Orthofix.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
News

Orthofix Reports Third Quarter 2023 Results

Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ:OFIX) entered into a new four-year financing agreement with a borrowing capacity of up to $150 million. The company reported net sales of $184.0 million, a 61% increase on a reported basis and an 8% increase on a pro forma basis. Adjusted EBITDA was $13.5 million, representing 36% sequential growth over the second quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
earnings
-
News

Orthofix Announces Full Commercial Launch of the WaveForm L Interbody System for Lateral Lumbar Fusion Procedures

Rhea-AI Summary
Orthofix Medical Inc. has announced the full U.S. commercial launch of the WaveForm® L Lateral Lumbar Interbody System. The 3D-printed system is designed for lateral lumbar interbody fusion (LLIF) procedures and features a porous structure for strength and stability. The system has improved imaging characteristics and is expected to contribute to the growing LLIF market, which is estimated to be over $350 million in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
News

Orthofix Schedules Third Quarter Earnings Release and Conference Call for November 8, 2023

Rhea-AI Summary
Orthofix Medical Inc. to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.66%
Tags
earnings
News

Orthofix Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for use in Spine and Orthopedic Procedures

Rhea-AI Summary
Orthofix Medical Inc. announces the clearance and launch of OsteoCove, an advanced bioactive synthetic graft.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
-
News

Orthofix Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Rhea-AI Summary
Orthofix Medical Inc. announces full U.S. commercial launch of Galaxy Fixation Gemini system for treating fractures resulting from trauma in limbs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
News

Orthofix Announces Leadership Changes

Rhea-AI Summary
Orthofix Medical Inc. announces leadership changes and postpones investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.17%
Tags
management
News

Orthofix to Participate in Morgan Stanley Healthcare Conference

Rhea-AI Summary
Orthofix Medical Inc. to present at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences

FAQ

What is the current stock price of Orthofix Medical (OFIX)?

The current stock price of Orthofix Medical (OFIX) is $19.13 as of November 27, 2024.

What is the market cap of Orthofix Medical (OFIX)?

The market cap of Orthofix Medical (OFIX) is approximately 746.5M.

What does Orthofix Medical Inc. specialize in?

Orthofix Medical Inc. specializes in orthopedic and spine solutions, offering a range of products for bone growth, fracture repair, and spinal treatments.

Where is Orthofix Medical Inc. headquartered?

Orthofix Medical Inc. is headquartered in the United States with additional locations in Italy, Germany, France, the UK, Brazil, Australia, and Puerto Rico.

What are the main business units of Orthofix?

The main business units are BioStim, Biologics, Extremity Fixation, and Spine Fixation.

How does Orthofix distribute its products?

Orthofix distributes its products through sales representatives, distributors, and subsidiaries across North America, Europe, and other international markets.

What partnerships does Orthofix have?

Orthofix has partnerships with organizations such as the Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation.

In how many countries are Orthofix products available?

Orthofix products are available in more than 70 countries around the world.

What segment generates the majority of Orthofix's sales?

The majority of Orthofix's sales come from the global spine segment, particularly in the United States.

What are some key products offered by Orthofix?

Key products include bone growth stimulators, spinal implants, regenerative tissue products, and devices for fracture repair and deformity correction.

How many employees does Orthofix have?

Orthofix has over 900 employees.

When was Orthofix Medical Inc. founded?

Orthofix Medical Inc. was founded in 1980 in Verona, Italy.

Stock OFIX logo
Orthofix Medical Inc.

Nasdaq:OFIX

OFIX Rankings

#2820 Ranked by Market Cap
N/A Ranked by Dividends

OFIX Stock Data

746.51M
36.31M
4.99%
92.32%
6.57%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
LEWISVILLE